You are here

  • Home
  • Archive
  • Volume 78, Issue 4
  • Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Article metrics

Article menu
Download PDFPDF
Rheumatoid arthritis
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

 

Online download statistics by month:

Online download statistics by month: January 2019 to December 2022

AbstractFullPdf
Jan 20191940197127
Feb 20193455334185
Mar 20192413398239
Apr 20191145279167
May 201965715096
Jun 20194598257
Jul 20194907334
Aug 20193085742
Sep 20193614934
Oct 20195088648
Nov 20194347450
Dec 20198516038
Jan 20205576050
Feb 20205467761
Mar 20208389874
Apr 202092512583
May 20207317967
Jun 20204486537
Jul 20206354541
Aug 20204755838
Sep 20203804735
Oct 20205455042
Nov 20203502824
Dec 20202683826
Jan 20214545439
Feb 20214924840
Mar 20214754835
Apr 20217234130
May 20213234742
Jun 2021483927
Jul 2021775427
Aug 2021574523
Sep 2021695125
Oct 20215797034
Nov 20214974724
Dec 20214503015
Jan 20223965930
Feb 20224013620
Mar 20224185422
Apr 20223992924
May 20223324124
Jun 20224395129
Jul 20222753119
Aug 20224603813
Sep 20224974623
Oct 20225314731
Nov 20223593916
Dec 2022490296
Total2896036832313